Recent Updates
Recently added Catalysts

CP-866, 087

Phase 2

Alcoholism | Small molecule | Psychiatry |Pfizer, Inc.|Last Updated: Oct 2, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment88

FDA Designations

No designations recorded

Clinical trial landscape

CP-866, 087 · 3 trials · 3 indications

Phase 2 3
NCT00482664The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.Sexual Dysfunction, Physiological
COMPLETED84 Analytics
NCT00479492Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, VolunteersObesity
COMPLETED94 Analytics
NCT00147576Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.Alcoholism
COMPLETED88 Analytics
PHASE2COMPLETED
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
Sexual Dysfunction, Physiological
NCT0048266484
Unlock trial analytics
PHASE2COMPLETED
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
Obesity
NCT0047949294
Unlock trial analytics
PHASE2COMPLETED
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Alcoholism
NCT0014757688
Unlock trial analytics

Study Endpoints

Primary Endpoints

Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks.
6 weeks
Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment.
6 weeks
Measure the effect of weight loss over 12 weeks in overweight otherwise healthy patients. Measurements will include body weight and waist circumference. Measurements will occur at Day 1, 7, 14, 28, 42, 56, 70, 84 and 94.
94 days
The amount of alcohol consumed will be based on the total number of standardized drinks consumed during a two-hour laboratory-based self-administration procedure following 7 days of treatment with study medication.

Secondary Endpoints

Exit interview at end of study. Meaningful Benefit Question at end of study.
End of study
Measure of Female Sexual Distress questionnaire after 6 weeks of treatment.
6 weeks
To characterize the effect of 4 weeks of dosing of 3 different doses of CP-866,087 on 24-hour urinary cortisol levels. Measured at Day 1 and Day 29
29 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1 mgEXPERIMENTAL -
10 mgEXPERIMENTAL -
3 mgEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
1EXPERIMENTAL -
2EXPERIMENTAL -
3EXPERIMENTAL -
4PLACEBO_COMPARATOR -

Interventions

NameTypeDescription
CP-866,087DRUGTablets for oral administration
PlaceboDRUGTablets for oral administration
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to 45 Years
SexFEMALE
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * healthy pre-menopausal women * primary female sexual arousal disorder causing distress * on stable use of oral contraceptives Exclusion Criteria: * any other significant disease causing Female Sexual Dysfunction including psychiatric disease * subjects on drugs known to caus...

Countries:AustraliaDenmarkNorwaySouth AfricaSwedenUnited States
Unlock Eligibility Criteria

Frequently asked questions about CP-866, 087

What is CP-866,087 used for?

CP-866,087 is an investigational small molecule being studied for obesity, physiological sexual dysfunction, and alcoholism. It is being developed by Pfizer, Inc. (PFE) and has completed Phase 2 clinical trials in these indications. The drug is not approved and remains in clinical development.

How does CP-866,087 work?

CP-866,087 is a small molecule being developed by Pfizer, Inc. (PFE). Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here. The drug has been studied in Phase 2 trials for obesity, sexual dysfunction, and alcoholism.

Who makes CP-866,087?

CP-866,087 is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule that has completed Phase 2 clinical trials for obesity, physiological sexual dysfunction, and alcoholism.

What phase is CP-866,087 in?

CP-866,087 is in Phase 2 clinical development. It has completed Phase 2 trials for obesity, physiological sexual dysfunction, and alcoholism, with no active trials currently listed. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials is CP-866,087 in?

CP-866,087 has completed three Phase 2 clinical trials: NCT00147576 studied its effect on alcohol consumption and craving in alcohol-dependent subjects; NCT00479492 evaluated its effects and safety in overweight volunteers; and NCT00482664 assessed its efficacy, safety, and toleration in pre-menopausal women with female sexual arousal disorder.